FDA “Approvable” Letter Requests Validation, Stability Data For Merck’s Emend IV
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will respond “within the next few months” to May 3 letter, Merck tells “The Pink Sheet” DAILY.
You may also be interested in...
GSK Files NDA For Oncology Anti-Nausea Drug
Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.
GSK Files NDA For Oncology Anti-Nausea Drug
Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.
Merck Anti-Emetic Emend Adds Postoperative Nausea Indication
Emend represents the first new class of therapy for the management of PONV in more than 10 years, Merck says.